Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 6,770 matching trials from the live ClinicalTrials.gov search.

Filters: Bethesda, Maryland Clear all

Conditions: Uveitis
Interventions: Daclizumab; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV-1
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: X-linked Myotubular Myopathy
Interventions: Not listed
Lead sponsor: Astellas Gene Therapies; Industry
Eligibility: Up to 3 Years · Male only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • Chicago, Illinois + 1 more

Conditions: Hemostasis
Interventions: HEMOBLAST Bellows, Absorbable gelatin sponge, USP with thrombin; Device
Lead sponsor: Biom'Up France SAS; Industry
Eligibility: 21 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Pasadena, California + 12 more

Conditions: Epilepsy
Interventions: Diazepam Buccal Film 12.5 mg; Drug
Lead sponsor: Aquestive Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 11
States / cities: Tucson, Arizona • Downey, California • New Haven, Connecticut + 8 more

Conditions: Brain Metastases
Interventions: Memantine, Hippocampal-avoidant (HA-WBRT) Radiotherapy, Stereotactic Radiosurgery (SRS); Drug · Radiation · Procedure
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 73
States / cities: Tucson, Arizona • Corona, California • Duarte, California + 63 more

Conditions: Normal Physiology
Interventions: 3T and 7T device; Device
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Disease
Interventions: Biosamples from airway and blood; Other
Lead sponsor: Boston University; Other
Eligibility: 50 Years to 79 Years
Enrollment: 665 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2027
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • Denver, Colorado + 9 more

Conditions: Gastroenteritis
Interventions: Omalizumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 76 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
Interventions: Capecitabine, Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Temozolomide; Drug · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2029
U.S. locations: 673
States / cities: Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more

Conditions: Alcohol Dependence, Alcoholism
Interventions: LY686017, Placebo; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Malignant Solid Tumors, Other Neoplasms Solid Tumors, Pediatric Solid Tumor, Refractory Solid Tumors, Solid Tumor
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 4 Weeks and older
Enrollment: 10,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2032
U.S. locations: 3
States / cities: Bethesda, Maryland • Portland, Oregon • Houston, Texas

Conditions: Viral Respiratory Infection, Viral Respiratory Illnesses
Interventions: INNA-051, Placebo; Drug · Other
Lead sponsor: ENA Respiratory Pty Ltd; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Baltimore, Maryland • Bethesda, Maryland • College Park, Maryland + 3 more

Conditions: Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma
Interventions: Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 27
States / cities: Birmingham, Alabama • Orange, California • San Francisco, California + 22 more

Conditions: Auditory Perceptual Disorder, Language Delay, Language Disorder
Interventions: Not listed
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: 6 Years to 85 Years
Enrollment: 875 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neutropenia, Agranulocytosis, Hematologic Diseases, Leukocyte Disorders, Leukopenia
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 5 Years to 99 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Lymphoblastic Leukemia
Interventions: Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 17,463 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 214
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more

Conditions: Psoriasis
Interventions: 13N Amonia; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years and older
Enrollment: 7,776 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2009
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • New Orleans, Louisiana + 4 more

Conditions: Asthma
Interventions: Fluticasone furoate 50mcg, Fluticasone propionate 100mcg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Los Angeles, California • Rolling Hills Estates, California • Sacramento, California + 17 more

Conditions: Healthy
Interventions: Docosahexaenoic acid (DHA), Eicosapentaenoic acid; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Malaria
Interventions: Pvs230D1-EPA/Matrix-M; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Developmental Delay Disorders, Chromosome Deletion, Mental Retardation, Sleep Disorders, Circadian Rhythm, Self Injurious Behavior
Interventions: dTR Melatonin (NIH CC PDS), Phototherapy (Bright Light), Melatonin CR; Drug · Device
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 3 Years to 45 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis

Interventions to Decrease the Risk of Mother-to-Child Transmission of HIV in India

Magnetic Resonance Imaging to Detect Brain Damage in Patients With Multiple Sclerosis

A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects

HEMOBLAST Pivotal Clinical Investigation

Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With Epilepsy

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

MRS Measurement of Glutamate and GABA Metabolism in Brain

DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer

Omalizumab to Treat Eosinophilic Gastroenteritis

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Effect of LY686017 on Alcohol Craving

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Hereditary Deficits in Auditory Processing Leading to Language Impairment

Natural History Study for BEN

Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Effect of Chronic Inflammation on Myocardial Perfusion and Function

Genetic Analysis of Hereditary Prostate Cancer

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma

Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress

Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive Adults

Treatment Strategies for Children With Smith-Magenis Syndrome